Roche invests $642M in new office/R&D unit
Swiss drug major Roche has unveiled plans for the further development of its headquarters in Basel. To bring those employees back to the Wettstein headquarters currently spread among the various other Basel sites, it is planning a new office high-rise building that will accommodate some 2,400 workplaces. In addition, an older laboratory unit no longer in use will be replaced by a new R&D building. The two projects will cost a total of 800.0 million Swiss francs ($642.5 million).
The high-rise office building will cost around 550.0 million francs and could be completed by 2011, with the R&D facility (with an investment of 250.0 million francs) likely ready in 2010, the firm says,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze